Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
BG505 SOSIP.664 gp140
- Development stage
- Phase 1
- Lead developer
- GSK
- Modality
- Recombinant Protein Vaccines → Recombinant Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics, Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Administration
- Intramuscular
01
Overview
BG505 SOSIP.664 gp140 is a next-generation, cleaved, glycosylated trimeric HIV-1 envelope glycoprotein immunogen designed to mimic the native structure of the HIV-1 Env spike protein[4][2][3]. The construct is based on the subtype A transmitted/founder virus sequence (BG505) and incorporates specific modifications—including an engineered disulfide bond (SOS), an I559P substitution for stability in pre-fusion conformation (IP), and truncation at residue 664—to stabilize the trimer and prevent aggregation[1][3]. The membrane-proximal external region (MPER) is deleted to improve solubility[3]. This recombinant protein displays epitopes for broadly neutralizing antibodies while occluding non-neutralizing antibody sites[3]. It is being developed primarily as a vaccine candidate for HIV infection prevention and has demonstrated immunogenicity in preclinical models as well as safety and immunogenicity in early-phase clinical trials[4][5].
- Other names
- BG505 SOSIP 664 gp140 adjuvanted vaccineBG-505 SOSIP 664 gp140 adjuvanted vaccineBG 505 SOSIP 664 gp140 adjuvanted vaccineBG505 SOSIP.664 gp140 VaccineBG-505 SOSIP.664 gp140 VaccineBG 505 SOSIP.664 gp140 Vaccine
02
Targets
Env (HIV-1 envelope glycoprotein)BCR-HIV-Env (HIV-1 envelope-specific B-cell receptor)
Beyond the preview
Go deeper on BG505 SOSIP.664 gp140.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on BG505 SOSIP.664 gp140.